SCHEMBL2092940

SCHEMBL2092940

[CH2]OC(=O)Nc1ccc(-c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.58
PTPN11 Q06124 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
MITF O75030 1/20 0.53
HTT P42858 1/20 0.53
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TAAR1 Q96RJ0 1/20 0.50
DEGS1 O15121 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
MEN1 O00255 2/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.47
PORCN Q9H237 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514783 0.88 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL2094873 0.84 MGLL (0.66) MEN1KMT2A
SCHEMBL2092941 0.82 SMN1; SMN2 (0.68) PTPN1PTPN11SMN1; SMN2ALDH1A1NPC1
SCHEMBL2096940 0.81 HPGD (0.72) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL2097448 0.80 SLC1A3 (0.51) PTPN1SMN1; SMN2NPC1RAB9ACA12
SCHEMBL30407133 0.79 ALDH1A1 (0.72) PTPN1PTPN11SMN1; SMN2ALDH1A1RAB9A
SCHEMBL9089988 0.78 MAPT (0.54) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT
SCHEMBL1177104 0.78 PTPN1 (0.64) PTPN1PTPN11SMN1; SMN2ALDH1A1NPC1
SCHEMBL2088959 0.77 RORC (0.49) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL6621497 0.77 PTPN1 (0.69) PTPN1PTPN11SMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PTPN1 1076/4885PTPN11 1696/4885SMN1; SMN2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.